"Administering CAR-T therapy isn’t like dispensing pills or infusing chemotherapy. Treating patients with CAR-T “requires an immense amount of planning and coordination and meetings,” says Fathi of Massachusetts General Hospital. He ticks off a long list of personnel who have to be in the loop, including cell processing experts, nurses, clinical trial coordinators, lab researchers, pharmacists, and physicians who specialize in infectious disease, pulmonary and critical care, and neurology.  "   

From the article "Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed?"

http://www.xconomy.com/national/2017/03/13/possible-cures-mystery-deaths-daunting-costs-can-car-t-be-tamed/?single_page=true

 

These advanced live cell therapies demand a new, "many-to-many" communication system because "a long list of personnel have to be in the loop".   As these therapies get closer to commercialization many parties are recognizing the need for a new approach as existing systems cannot offer a solution.  Cold chain 1.0 is a "1-1" communication system (shipping clerk to shipping clerk), where data are received post-transport and generally relying on manual notification to stakeholders after-the-fact.  The evo® Cold Chain 2.0™ communication system is uniquely designed specifically for the challenges of moving live cell therapies - across campus, across country, or across the globe.   It simplifies the task of keeping many parties in the loop by transmitting real-time (or near real-time) data to assignable key personnel, providing timely, relevant, and actionable information.